Long-Term Follow-Up for Cancer

Recruiting at 163 trial locations

Age: Any Age

Sex: Any

Trial Phase: Academic

Sponsor: Children's Oncology Group

Disqualifiers: Non-U.S. residence, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

5000 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to gather long-term information from patients who participated in past studies with the Children's Oncology Group. The goal is to understand the long-term effects of cancer treatments, helping doctors improve care and reduce future treatment-related problems. Participants will complete health questionnaires to track their current health and any complications from past cancer therapies. This trial is suitable for U.S. residents who have participated in a Children's Oncology Group study and are willing to provide ongoing health updates. As an unphased trial, this study offers participants the opportunity to contribute valuable insights that can enhance future cancer care and treatment strategies.

Do I need to stop taking my current medications for this trial?

The trial information does not specify whether you need to stop taking your current medications.

Why are researchers excited about this trial?

Researchers are excited about this trial because it focuses on the long-term follow-up of patients who have participated in Children's Oncology Group studies, providing valuable insights into therapy complications over time. Unlike other approaches that may not systematically track patient outcomes long after treatment, this protocol emphasizes continuous monitoring and data collection through annual health status updates. This method could lead to a better understanding of the long-term effects of cancer therapies, ultimately helping to improve future treatments and patient care.

Who Is on the Research Team?

Smita Bhatia

Principal Investigator

Children's Oncology Group

Are You a Good Fit for This Trial?

Inclusion Criteria

The patient must reside in the U.S. on the date of enrollment to ALTE05N1

All patients and/or their parents or legal guardians must sign a written informed consent

All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be me

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Initial Contact

Within 3 months of enrollment, patients receive a packet introducing the Long-Term Follow-Up Center and are asked to complete a patient response form and update contact and health status information.

3 months

Long-Term Follow-up

Patients are contacted annually to update contact and health status information, and to collect protocol-specific outcome data.

Up to 20 years

What Are the Treatments Tested in This Trial?

Interventions

• Assessment of Therapy Complications
• Questionnaire Administration

How Is the Trial Designed?

Group I: Observational (long-term follow-up) Experimental Treatment 2 Interventions

Within 3 months of enrollment on ALTE05N1, patients receive a packet introducing the Long-Term Follow-Up Center (LTFC). Patients are asked to complete a patient response form, verify information provided in packet, and update contact and health status information. The Health Status Update Form is a brief document including questions about current health status, disease status, and cancer therapy received since the last mailing. Patients may respond by use of postage prepaid envelopes, secure online form, or 24-hour toll-free telephone number. After initial contact, the LTFC will contact the patient annually

Who Is Running the Clinical Trial?

Children's Oncology Group

Lead Sponsor

Trials

467

Recruited

241,000+

National Cancer Institute (NCI)

Collaborator

Trials

14,080

Recruited

41,180,000+